An increase indicates active portfolio optimization or divestiture of underperforming assets.
The portion of goodwill associated with a specific business unit that is derecognized from the balance sheet upon the di...
Standard for companies undergoing restructuring or strategic portfolio realignment.
jpm_goodwill_written_off_sale_of_business| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Oncology & Multispecialty | $0.00 | $0.00 | — | — | — | $2.25M | $2.25M | $2.25M |
| International | — | — | — | $11.50M | $0.00 | — | — | — |
| Medical-Surgical Solutions | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| North American Pharmaceutical | $11.50M | $11.50M | — | — | — | — | $0.00 | $0.00 |
| Prescription Technology Solutions | $0.00 | $0.00 | — | — | — | $0.00 | $0.00 | $0.00 |
| Total | — | — | — | — | — | — | — | — |
Oncology & Multispecialty is derived from annual filings.
Corporate, International, U.S. Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.